Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Antibody therapeutics are a large and rapidly expanding drug class providing major health
benefits. We provide a snapshot of current antibody therapeutics including their formats …

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

The blood-brain barrier (BBB) prevents neurotoxic plasma components, blood cells, and
pathogens from entering the brain. At the same time, the BBB regulates transport of …

Therapies directed toward the central nervous system remain difficult to translate into
improved clinical outcomes. This is largely due to the blood–brain barrier (BBB), arguably …

Alzheimer's disease (AD) and treatment of the brain in aging require the development of
new biologic drugs, such as recombinant proteins or gene therapies. Biologics are large …

Brain exposure of systemically administered biotherapeutics is highly restricted by the blood-
brain barrier (BBB). Here, we report the engineering and characterization of a BBB transport …

Effective delivery of protein therapeutics to the central nervous system (CNS) has been
greatly restricted by the blood-brain barrier (BBB). We describe the development of a BBB …

One of the biggest challenges in the development of therapeutics for central nervous system
(CNS) disorders is achieving sufficient blood–brain barrier (BBB) penetration. Research in …

The formulation and delivery of biopharmaceutical drugs, such as monoclonal antibodies
and recombinant proteins, poses substantial challenges owing to their large size and …